Biomark's Collaborator Receives Funding to Validate Its Biomarker Panel for the Early Detection of Lung Cancer
Vancouver, British Columbia--(Newsfile Corp. - March 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its sponsored research collaboration with The Metabolomics Innovation Centre (TMIC) was successful in receiving funding from the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research - Institute of Cancer Research, and Brain Canada Foundation,...
2021-03-16 8:30 AM EDT
BioMark Grants Options
Vancouver, British Columbia--(Newsfile Corp. - March 2, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that it has granted 2,100,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each option is exercisable into one common share at a price of $0.25 per share and will vest immediately. The options will expire two...
2021-03-02 8:30 AM EST
BioMark and Phytronix Technologies Inc. Enter into a Collaborative Research and Development Agreement
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. has entered into a collaborative research and development agreement with Phytronix Technologies Inc. ("Phytronix") to advance the development of BioMark's early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology. While BioMark Diagnostic Solutions is preparing to offer lab services and metabolomics capabilities in Quebec...
2021-02-16 8:30 AM EST
BioMark Diagnostics Targets Response to Treatment Application with Its Liquid Biopsy Platform
Vancouver, British Columbia--(Newsfile Corp. - February 8, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that the article "Use of Amantadine in the Evaluation of Response to Chemotherapy in Lung Cancer - a Pilot Study" has been published in the peer-reviewed journal Future Science OA.Rashid A. Bux, President and CEO of BioMark, says, "This publication shows the potential of our liquid biopsy platform's ability to provide a novel and low-cost test...
2021-02-08 8:30 AM EST
Alfred Berkeley Joins BioMark's Advisory Team
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark") is glad to announce Alfred Berkeley as a new member of the BioMark's Advisory team, as he will be providing strategic and financial advice to help expand the company's commercialization effort in the U.S.Mr. Rashid Ahmed Bux, CEO and President of BioMark Diagnostics says: "We are extremely proud and honored to have Mr. Berkeley join our advisory group at this moment....
2021-01-11 8:30 AM EST
BioMark Retains Questrade, Inc. to Provide Market-Making Services
Vancouver, British Columbia--(Newsfile Corp. - December 7, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that it has retained Questrade, Inc. ("Questrade") to provide market-making services in accordance with CSE guidelines.The term of the agreement is for one year, beginning December 7, 2020 at a cost of CAD $3,000 per month. Either party may terminate the agreement with 30 days written notice. Though BioMark and Questrade are unrelated and unaffiliated entities and Questrade will...
2020-12-07 8:30 AM EST
BioMark Scientific Advisor Dr. Donald Miller to Present at the Delaware Valley Drug Metabolism Discussion Group
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark's SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion Group (DVDMDG).Rashid Ahmed, President and CEO of BioMark, says, "We are pleased to have Dr. Donald Miller present his important work on the...
2020-09-23 8:30 AM EDT
BioMark Appoints Dr. Jean-Francois Haince as Strategic Advisor to Guide Its Expansion into Quebec
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team. Rashid Ahmed, President and CEO, says, "We are delighted to welcome Dr. Haince into our advisory team. Jeff brings a pragmatic perspective to our bench strength along with a thorough understanding of engaging within the vibrant biotech ecosystem in Quebec...
2020-09-16 8:30 AM EDT
BioMark Team Invited for Full Application for Sparks Grant Competition
Vancouver, British Columbia--(Newsfile Corp. - September 14, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This comes after the organizers of the competition, the Canadian Cancer Society/Canadian Institutes of Health Research - Institute of Cancer Research, and Brain...
2020-09-14 8:30 AM EDT
BioMark Team Secures Health Canada Letter of No Objection for Its Glioblastoma Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA.The company would like to thank Dr. Marshall Pitz the principal investigator and is the Section Head of Clinical Research at the Research Institute at CancerCare...
2020-08-27 8:30 AM EDT
BioMark Diagnostics Expands Research Development in Quebec
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP, an incubator-accelerator dedicated to tech businesses growth and mentorship."This move highlights BioMark's focus on diagnostic development and technological innovation within the healthcare sector," said Rashid Bux, Chief Executive Officer of BioMark...
2020-08-13 8:30 AM EDT
BioMark's Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that its affiliated company, Bio-Stream Diagnostics Inc., will be working with University of Qatar's Dr. Somaya Al-Maadeed in the development of its novel COVID-19-detection method, leveraging new generation Raman spectroscopy and the power of machine learning. Raman spectroscopy is a spectroscopic technique typically used to determine vibrational modes of molecules, although rotational and other low-frequency modes of...
2020-07-21 8:30 AM EDT
BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name "BioMark"
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name "BioMark". The term "BioMark" was selected by the company in reference to their Biomarker Testing capabilities in the fields of cancer treatment and anti-cancer preparations. Biomarker testing is comprised of a group of...
2020-07-16 8:30 AM EDT
BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer diagnostic platform that repurposes a U.S. Food and Drug Administration (FDA) off patent drug for a new application.BioMark's team recently published an article...
2020-06-23 8:30 AM EDT
BioMark Receives European Patent for Cancer Diagnostic
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announced today that the company has been granted a patent titled "A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE." The method comprises correlating a presence of the acetylated metabolite of rimantadine or tocainide to spermidine/spermine N1-acetyltransferase activity. The patent will cover a novel approach to diagnosing and monitoring various forms of cancer.Cancer is one of the...
2020-06-18 8:30 AM EDT
Bio Stream Diagnostics Inc. Selected for CDL Rapid Response Innovation Program
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce that its affiliated company, Bio Stream Diagnostics Inc., was selected to participate in the global academic science and tech startup program Creative Destruction Lab's (CDL) recent dedicated Recovery program. CDL Recovery is designed to help turn science and research work into scalable products and services to address the consequences of the COVID-19 pandemic, in...
2020-06-16 8:30 AM EDT
BioMark Diagnostics Inc. Clarifies Prior Disclosure
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, wishes to include additional information to clarify the disclosures in its news release disseminated by the Company on June 10, 2020 with respect to the formation of Bio Stream Diagnostics Inc., a new company, focused on providing low-cost...
2020-06-11 5:37 PM EDT
BioMark Diagnostics Forms New Company, Bio Stream Diagnostics Inc., for '30-Second' COVID-19 Screening
Vancouver, British Columbia--(Newsfile Corp. - June 10, 2020) - BioMark Diagnostics Inc.(CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, announced today that the Company has partnered with Stream.ML and Merogenomics to form Bio Stream Diagnostics Inc., a new company, focused on providing low-cost COVID-19 detection in less-than-30 seconds. Leveraging Raman spectroscopy and the power of machine learning, the...
2020-06-10 8:30 AM EDT
BioMark Announces Filing of Amended and Restated MD&A for the Three and Nine Months Ended December 31, 2019
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - As a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) ("BioMark")announced it has amended and restated its interim management discussion and analysis (the "Interim MD&A") for the three and nine months ending December 31, 2019. The Interim MD&A has been amended to clarify and expand upon the qualitative discussion...
2020-05-29 4:30 PM EDT
BioMark's Liquid Biopsy Assay Levering Metabolomics Demonstrates Strong Performance for Early Lung Cancer Detection
Vancouver, British Columbia--(Newsfile Corp. - March 24, 2020) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC PINK: BMKDF) ("BioMark") is pleased to announce that the article "A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection" has been published in the peer-reviewed journal Cancers, validating BioMark's technology to detect early-stage (I/II) non-small cell lung cancer (NSCLC) using a simple blood plasma test.Rashid Bux, President and CEO, says, "This latest publication demonstrates our ability to further leverage our international team...
2020-03-24 6:30 AM EDT